arrow
Z

Ziad Hijazi

Uppsala University
H指数:44
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference

通过针对合并症并减少心房颤动负荷来改变心房颤动管理:第10届AFNET/EHRA共识会议

2025-12-010
PRE
Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation

基于注册研究的随机对照试验的合理性及设计:个性化生物标志物为基础的风险评分指导下的房颤卒中预防治疗

2025-06-230
OAAI
Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)

缺血性卒中和心房颤动后抗凝治疗最佳时机的合作:一项系统综述和随机对照试验的前瞻性个体参与者数据meta分析(CATALYST)

2025-06-230
OA
Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

基于生物标志物的房颤患者缺血性卒中预测模型

2025-03-010
PRE
Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

心房颤动患者的更长寿和更好的生活: 第九届AFNET/EHRA共识会议

2024-04-0918
OAAI
Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

重复测量新型心房生物标志物BMP10 (骨形态发生蛋白10) 可改善房颤抗凝患者的风险分层: 来自ARISTOTLE试验的见解

2024-04-022
OAAI
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

直接口服抗凝剂与华法林在肾功能范围内的比较: 联合房颤患者水平的网络荟萃分析

2023-06-0632
OA
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

口服抗凝药时心房颤动和缺血性卒中患者的预后

2023-04-1130
PRE
Data standards for atrial fibrillation/flutter and catheter ablation: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
2022-10-155
OAAI